Skip to main content

Minerva Neurosciences, Inc. (NERV)

NASDAQ: NERV · Delayed Price · USD
0.938
0.065 (7.49%)
At close: Dec 7, 2021 4:00 PM
0.922
-0.016 (-1.727%)
After-hours:Dec 7, 2021 6:36 PM EST
Market Cap40.08M
Revenue (ttm)n/a
Net Income (ttm)-35.92M
Shares Out42.72M
EPS (ttm)-0.84
PE Ration/a
Forward PE11.21
Dividendn/a
Ex-Dividend Daten/a
Volume228,086
Open0.910
Previous Close0.873
Day's Range0.880 - 0.970
52-Week Range0.832 - 3.750
Beta0.93
AnalystsBuy
Price Target7.00 (+646.1%)
Earnings DateNov 8, 2021

About NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma C...

IndustryBiotechnology
IPO DateJul 1, 2014
CEORemy Luthringer
Employees11
Stock ExchangeNASDAQ
Ticker SymbolNERV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for NERV stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 646.11% from the latest price.

Price Target
$7.00
(646.11% upside)
Analyst Consensus: Buy

News

Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Company to Host Conference Call Today at 8:30 a.m. ET

4 weeks ago - GlobeNewsWire

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as ...

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...

1 month ago - GlobeNewsWire

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

Management to Host Conference Call Management to Host Conference Call

1 month ago - GlobeNewsWire

Minerva Neurosciences Announces Promotion of Geoff Race to President

Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA

1 month ago - GlobeNewsWire

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

Minerva Neurosciences Inc (NASDAQ: NERV) announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned commercial formulation.  Re...

2 months ago - Benzinga

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commerci...

Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration

2 months ago - GlobeNewsWire

Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of -47.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...

4 months ago - GlobeNewsWire

Analysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for

Minerva Neurosciences (NERV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

Management to host conference call Management to host conference call

4 months ago - GlobeNewsWire

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat centr...

5 months ago - GlobeNewsWire

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat centra...

6 months ago - GlobeNewsWire

Minerva Neurosciences (NERV) Enters Overbought Territory

Minerva Neurosciences (NERV) has moved higher as of late, but there could definitely be trouble on the horizon for this company

6 months ago - Zacks Investment Research

Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't?

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Best Penny Stocks to Buy During a Market Correction? Check These 4 Out

Looking for penny stocks to buy during a market correction? Check these 4 out for your watchlist The post Best Penny Stocks to Buy During a Market Correction?

Other symbols:CYRNOPKWTRH
6 months ago - PennyStocks

Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May

Biotech penny stocks are heating up right now; here's 4 to watch The post Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other symbols:EVFMNOVN
6 months ago - PennyStocks

Minerva (NERV) Soars on Promising Schizophrenia Study Data

Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boos...

6 months ago - Zacks Investment Research

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, impr...

6 months ago - GlobeNewsWire

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Sympto...

WALTHAM, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous s...

6 months ago - GlobeNewsWire

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021

Management to host conference call Management to host conference call

7 months ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock?

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021

8 months ago - GlobeNewsWire

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc...

LOS ANGELES, Feb. 8, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc. ("Minerva...

9 months ago - PRNewsWire